Loading...
VOR logo

Vor Biopharma Inc.NasdaqGS:VOR Stock Report

Market Cap US$785.2m
Share Price
US$14.49
US$37.88
61.7% undervalued intrinsic discount
1Y201.5%
7D0.9%
1D
Portfolio Value
​
View

Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$785.2m

Vor Biopharma (VOR) Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. More details

VOR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the US market

+ 1 more risk

VOR Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Vor Biopharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vor Biopharma
Historical stock prices
Current Share PriceUS$14.49
52 Week HighUS$65.80
52 Week LowUS$4.29
Beta1.73
1 Month Change-6.82%
3 Month Change20.35%
1 Year Change201.50%
3 Year Change-83.19%
5 Year Change-96.60%
Change since IPO-98.07%

Recent News & Updates

Analysis Article • May 15

Companies Like Vor Biopharma (NASDAQ:VOR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Vor Biopharma...

Recent updates

Analysis Article • May 15

Companies Like Vor Biopharma (NASDAQ:VOR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Vor Biopharma...
Seeking Alpha • Dec 18

Vor Biopharma: Initiating Hold Rating On Durable Telitacicept MG Study Data

Summary Vor Biopharma is initiated to "Hold" rating as topline phase 3 MG data for telitacicept is expected in H1 2027. Telitacicept demonstrated a best-in-disease MG-ADL reduction of -4.8 at week 24 and -7.5 at week 48 in a phase 3 China study. Company's recent $150M private placement extends its cash runway into Q2 2027, supporting global MG and pSD phase 3 trials. VOR's key risks include potential failure to replicate China's efficacy in global trials and regulatory uncertainty in the US, EU, and Japan. Read the full article on Seeking Alpha
Analysis Article • Oct 11

Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price

Key Insights The projected fair value for Vor Biopharma is US$48.35 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Sep 11

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jun 25

Calculating The Intrinsic Value Of Vor Biopharma Inc. (NASDAQ:VOR)

Key Insights Vor Biopharma's estimated fair value is US$0.31 based on 2 Stage Free Cash Flow to Equity Current share...
Analysis Article • Apr 08

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 24

Vor Biopharma: Short On Cash, Too Much Uncertainty For Now

Summary Vor Biopharma is developing novel cell therapies for AML, with trem-cel showing early promise in clinical trials but facing significant funding challenges. Trem-cel aims to enhance relapse-free survival in AML by targeting CD33 on cancer cells while minimizing bone marrow damage. Despite a recent private placement extending their runway, VOR's cash position remains precarious, posing a risk of dilution and market volatility. Given the early stage of their therapies and financial hurdles, I recommend holding off on investment until further developments in 2025. Read the full article on Seeking Alpha
Analysis Article • Dec 24

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Sep 10

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 24

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 05

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Aug 18

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • May 05

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 13

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Key Insights Vor Biopharma's estimated fair value is US$9.25 based on 2 Stage Free Cash Flow to Equity Vor Biopharma's...
Analysis Article • Oct 19

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 12

Vor Bio appoints Eyal C. Attar as chief medical officer

Vor Bio (NASDAQ:VOR) appoints more than 20 years of demonstrated clinical experienced Eyal C. Attar as Chief Medical Officer.  Dr. Attar most recently served as senior vice president and CMO for Aprea Therapeutics.
Analysis Article • Jun 18

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

VORUS BiotechsUS Market
7D0.9%1.3%1.7%
1Y201.5%31.1%25.1%

Return vs Industry: VOR exceeded the US Biotechs industry which returned 30.5% over the past year.

Return vs Market: VOR exceeded the US Market which returned 23.3% over the past year.

Price Volatility

Is VOR's price volatile compared to industry and market?
VOR volatility
VOR Average Weekly Movement12.3%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: VOR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VOR's weekly volatility has decreased from 24% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201576Jean-Paul Kresswww.vorbio.com

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd.

Vor Biopharma Inc. Fundamentals Summary

How do Vor Biopharma's earnings and revenue compare to its market cap?
VOR fundamental statistics
Market capUS$785.15m
Earnings (TTM)-US$883.08m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.9x
P/E Ratio

Is VOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VOR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$883.08m
Earnings-US$883.08m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-16.30
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VOR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/19 21:18
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vor Biopharma Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Justin WalshB. Riley Securities, Inc.